Immunic (IMUX) Total Current Liabilities (2013 - 2026)

Immunic has disclosed Total Current Liabilities across 14 years of filings, most recently posting $38.4 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $38.4 million, up 49.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.4 million (up 49.9% YoY), and the FY2025 annual result was $30.6 million, up 38.07% from the prior year.
• Total Current Liabilities came in at $38.4 million for Q1 2026 at Immunic, up from $30.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $38.4 million in Q1 2026 to a low of $10.4 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $22.2 million (2024), against an average of $21.4 million.
• Across the five-year window, Total Current Liabilities fell 29.95% in 2022 and soared 89.1% in 2023, its largest moves.
• Immunic's Total Current Liabilities stood at $13.1 million in 2022, then jumped by 89.1% to $24.7 million in 2023, then dropped by 10.33% to $22.2 million in 2024, then surged by 38.07% to $30.6 million in 2025, then gained by 25.3% to $38.4 million in 2026.
• The last three Total Current Liabilities figures came in at $38.4 million (Q1 2026), $30.6 million (Q4 2025), and $30.1 million (Q3 2025), per Business Quant data.